Dermatology · New York, NY
NPI
1265677033
Since 2008
Specialty
Dermatology
Code 207N00000X
Group practices
2
Medicare group memberships
Hospitals
3
Hospital affiliations
5 E 98th St
New York, NY, 10029
Phone (212) 659-9210
Groups this clinician bills Medicare through
Medicare paid, 2024
$113K
1,332 services
Medicare patients, 2024
385
Average age 74
Drug cost, 2024
$3.2M
1,316 prescriptions
Company payments, 2025
$693K
From 29 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Saakshi Khattri was code 99214 (office e&m - established), 264 times for 174 patients. In total Saakshi Khattri billed 1,332 services in 34 codes, and Medicare paid $113K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-06-27.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 264 | 174 | $96.14 | $25K |
| 17003 Destruction Skin Lesion | Office | 207 | 39 | $5.93 | $1,228 |
| 96910 Skin | Office | 177 | 31 | $107.75 | $19K |
| 99215 Office E&M - Established | Office | 146 | 76 | $156.65 | $23K |
| 96920 Skin | Office | 71 | 12 | $137.78 | $9,782 |
| 17000 Destruction Skin Lesion | Office | 70 | 54 | $48.86 | $3,420 |
| 11102 Skin Biopsy | Office | 60 | 57 | $85.49 | $5,130 |
| 99222 Hospital E&M - Initial | Facility | 58 | 56 | $112.42 | $6,520 |
| 99213 Office E&M - Established | Office | 43 | 41 | $66.61 | $2,864 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 40 | 38 | $13.94 | $558 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 37 | 32 | $28.55 | $1,056 |
| 99204 Office E&M - New | Office | 25 | 25 | $138.37 | $3,459 |
| 99205 Office E&M - New | Office | 19 | 19 | $196.10 | $3,726 |
| 99231 Hospital E&M - Subsequent | Facility | 18 | 13 | $43.21 | $778 |
| 17110 Destruction Skin Lesion | Office | 18 | 17 | $93.17 | $1,677 |
By year: 2022 $79K for 797 services; 2023 $114K for 1,185 services; 2024 $113K for 1,332 services.
Medicare prescription drug claims, 2024
In 2024, the drug Saakshi Khattri prescribed most often to Medicare patients was Dupixent Pen (Dupilumab), with 107 prescriptions and refills. In total Saakshi Khattri wrote 1,316 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dupixent Pen Dupilumab | 107 | 118 | 14 | $455K |
| Mupirocin Generic | 97 | 100 | 69 | $915 |
| Ketoconazole Generic | 95 | 104 | 46 | $5,404 |
| Triamcinolone Acetonide Generic | 93 | 101 | 59 | $1,196 |
| Minoxidil Generic | 74 | 178 | 23 | $770 |
| Clobetasol Propionate Generic | 52 | 69 | 33 | $2,075 |
| Dupixent Syringe Dupilumab | 40 | 40 | Under 11 | $157K |
| Tacrolimus Generic | 38 | 43 | 23 | $6,732 |
| Methotrexate Methotrexate Sodium | 36 | 61 | Under 11 | $807 |
| Hydroxychloroquine Sulfate Generic | 31 | 69 | Under 11 | $1,706 |
| Rinvoq Upadacitinib | 30 | 30 | Under 11 | $189K |
| Cosentyx Sensoready (2 Pens) Secukinumab | 28 | 28 | Under 11 | $220K |
| Hydrocortisone Generic | 28 | 30 | 21 | $196 |
| Doxycycline Hyclate Generic | 27 | 46 | 15 | $860 |
| Xolair Omalizumab | 24 | 24 | Under 11 | $46K |
Brand drugs: - claims; generic drugs: 823 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Saakshi Khattri $693K ($693K in general payments such as food, travel and fees) from 29 companies. The largest payer was Abbvie Inc. with $161K.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 114 | $161K |
| Janssen Biotech, Inc. JNJ | 67 | $96K |
| Regeneron Healthcare Solutions, Inc. REGN | 48 | $93K |
| Lilly USA, LLC LLY | 62 | $80K |
| UCB, Inc. UCB.BR | 72 | $75K |
| Pfizer Inc. PFE | 40 | $44K |
| Arcutis Biotherapeutics, Inc. ARQT | 42 | $42K |
| Genzyme Corporation SNY | 19 | $25K |
| Amgen Inc. AMGN | 23 | $20K |
| E.R. Squibb & Sons, L.L.C. BMY | 19 | $15K |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.